OMERS ADMINISTRATION Corp Purchases Shares of 116,900 Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

OMERS ADMINISTRATION Corp acquired a new position in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 116,900 shares of the company's stock, valued at approximately $374,000. OMERS ADMINISTRATION Corp owned approximately 0.24% of Checkpoint Therapeutics as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. SBI Securities Co. Ltd. acquired a new stake in Checkpoint Therapeutics during the 4th quarter worth approximately $32,000. PUREfi Wealth LLC purchased a new stake in Checkpoint Therapeutics during the fourth quarter valued at about $32,000. Stifel Financial Corp purchased a new stake in Checkpoint Therapeutics during the fourth quarter valued at about $32,000. Tower Research Capital LLC TRC lifted its holdings in Checkpoint Therapeutics by 157.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company's stock valued at $34,000 after purchasing an additional 6,486 shares during the last quarter. Finally, Boothbay Fund Management LLC purchased a new stake in Checkpoint Therapeutics during the fourth quarter valued at about $35,000. 22.00% of the stock is currently owned by institutional investors and hedge funds.

Checkpoint Therapeutics Price Performance

NASDAQ CKPT traded up $0.02 on Friday, reaching $4.19. 2,306,905 shares of the company's stock traded hands, compared to its average volume of 1,284,069. Checkpoint Therapeutics, Inc. has a 12 month low of $1.75 and a 12 month high of $4.50. The stock has a 50-day simple moving average of $4.08 and a 200 day simple moving average of $3.65. The stock has a market cap of $350.97 million, a PE ratio of -2.28 and a beta of 1.18.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.09). As a group, analysts anticipate that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. HC Wainwright restated a "neutral" rating and set a $4.10 price target on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th. D. Boral Capital restated a "buy" rating and issued a $4.80 price objective on shares of Checkpoint Therapeutics in a research report on Monday, March 31st. Finally, Lake Street Capital restated a "hold" rating and issued a $4.10 price objective (down from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th.

Insider Transactions at Checkpoint Therapeutics

In related news, CFO William Garrett Gray sold 12,322 shares of the firm's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $4.05, for a total value of $49,904.10. Following the completion of the sale, the chief financial officer now owns 1,446,322 shares of the company's stock, valued at $5,857,604.10. This trade represents a 0.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO James F. Oliviero III sold 15,090 shares of the firm's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $4.04, for a total value of $60,963.60. Following the completion of the sale, the chief executive officer now directly owns 3,759,929 shares of the company's stock, valued at $15,190,113.16. The trade was a 0.40% decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.10% of the company's stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.